The invention relates to a sustained-release formulation for oral administration comprising a substance chosen from pindolol and an ester of 4-(213-benzoxadiazol-4-yl)-14-dihydroxy-26-dimethyl- 35-pyridinedicarboxylic acid a pharmaceutically acceptable hydrophilic swelling substance and optionally a pharmaceutically acceptable inert fat.